GlassScriptPhysician profile
Charis P Taylor
NPI 1407036734
$2,483.06
in general payments reported to CMS, 2019-2025
28 companies · $261 in 2025
The $261 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $716 · 2020: $566 · 2021: $543 · 2023: $134 · 2024: $264 · 2025: $261.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $659.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $658.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $483.47 | 2019-2024 | Farxiga, Breztri |
| Novo Nordisk INC | $366.41 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $226.82 | 2019-2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $199.36 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $150.38 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $142.72 | 2019-2021 | |
| Pfizer INC. | $131.93 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $115.39 | 2020-2021 | |
| Medtronic, INC. | $88.06 | 2023-2025 | Intellis Adaptivestim |
| Boston Scientific Corporation | $79.64 | 2023-2024 | Wavewriter Alpha Prime 16, Spectra Wavewriter |
| Abbvie INC. | $71.38 | 2021-2025 | |
| Abbott Laboratories | $46.40 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $41.30 | 2025 | Rexulti |
| Dexcom, INC. | $38.75 | 2019-2021 | |
| Corcept Therapeutics | $36.86 | 2025 | Korlym |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arbor Pharmaceuticals, INC. | $31.53 | 2019 | |
| Antares Pharma, INC. | $30.03 | 2024-2025 | Xyosted |
| Recordati_rare_diseases_inc. | $26.54 | 2025 | Isturisa |
| Noven Therapeutics, LLC | $24.85 | 2024 | Xelstrym |
| Ascensia Diabetes Care US INC. | $24.36 | 2024 | |
| Stryker Corporation | $21.93 | 2025 | Clottriever Bold Catheter |
| Eisai INC. | $18.33 | 2020 | |
| Sumitomo Pharma America, INC. | $18.08 | 2023 | Gemtesa |
| Janssen Pharmaceuticals, INC | $18.01 | 2021 | |
| Inari Medical, INC. | $14.84 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| E.R. Squibb & Sons, L.L.C. | $12.92 | 2020 | |
| Merck Sharp & Dohme LLC | $11.49 | 2019 | |
| Philips North America LLC | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Charis Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.